Light Chain (AL) Amyloidosis
specificThe most common type of amyloidosis. It is characterized by the monoclonal deposition of immunoglobulin light chain fragments in organs and tissues. It is associated with plasma cell or B-cell lymphoproliferative disorders.
13
Centers
12
Active Trials
$396K
Cancer Funding
Top Centers for Light Chain (AL) Amyloidosis(13)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 54.2 |
| 2 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive Active Research Program | 54.2 |
| 3 | Siteman Cancer CenterSt. Louis, MO NCI Comprehensive Active Research Program | 54.2 |
| 4 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive Active Research Program | 54.2 |
| 5 | Masonic Cancer CenterMinneapolis, MN NCI Comprehensive Active Research Program | 54.2 |
| 6 | City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive Active Research Program | 54.2 |
| 7 | Huntsman Cancer Institute at the University of UtahSalt Lake City, UT NCI Comprehensive Active Research Program | 54.2 |
| 8 | Cleveland Clinic Cancer CenterCleveland, OH Active Research Program | 54.2 |
| 9 | The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive Active Research Program | 54.2 |
| 10 | Boston University Cancer CenterBoston, MA Active Research Program | 54.2 |
| 11 | Karmanos Cancer InstituteDetroit, MI NCI Comprehensive Active Research Program | 54.2 |
| 12 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 54.2 |
| 13 | Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive Active Research Program | 49.2 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →